141 related articles for article (PubMed ID: 33594990)
1. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
Leijten NM; Bakker P; Spaink HP; den Hertog J; Lemeer S
Mol Cell Proteomics; 2021; 20():100033. PubMed ID: 33594990
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract][Full Text] [Related]
4. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
5. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
Shao Z; Wang H; Ren H; Sun Y; Chen X
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
[TBL] [Abstract][Full Text] [Related]
6. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
7. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
8. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
10. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
11. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
[TBL] [Abstract][Full Text] [Related]
12. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
16. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
[TBL] [Abstract][Full Text] [Related]
17. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
18. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
Jonker DJ; Nott L; Yoshino T; Gill S; Shapiro J; Ohtsu A; Zalcberg J; Vickers MM; Wei AC; Gao Y; Tebbutt NC; Markman B; Price T; Esaki T; Koski S; Hitron M; Li W; Li Y; Magoski NM; Li CJ; Simes J; Tu D; O'Callaghan CJ
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):263-270. PubMed ID: 29397354
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid signaling plays a restrictive role in zebrafish primitive myelopoiesis.
Liang D; Jia W; Li J; Li K; Zhao Q
PLoS One; 2012; 7(2):e30865. PubMed ID: 22363502
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors.
Kawazoe A; Kuboki Y; Bando H; Fukuoka S; Kojima T; Naito Y; Iino S; Yodo Y; Doi T; Shitara K; Yoshino T
Cancer Chemother Pharmacol; 2020 May; 85(5):855-862. PubMed ID: 32236642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]